Veracyte (NASDAQ:VCYT) Stock Rating Lowered by Leerink Partners

Veracyte (NASDAQ:VCYT) was downgraded by investment analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Thursday, Briefing.com reports. They currently have a $35.00 target price on the biotechnology company’s stock. Leerink Partners‘s price objective suggests a potential downside of 33.36% from the stock’s current price.

VCYT has been the topic of several other reports. Piper Sandler decreased their price target on shares of Veracyte from $66.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Zacks Research cut shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Veracyte in a report on Tuesday, September 15th. Stephens decreased their price objective on Veracyte from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Finally, UBS Group lifted their target price on Veracyte from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.70.

Veracyte Trading Up 4.4%

VCYT opened at $52.52 on Thursday. The stock’s 50 day simple moving average is $44.90 and its 200-day simple moving average is $43.04. The stock has a market cap of $4.22 billion, a PE ratio of 37.25 and a beta of 1.98. Veracyte has a 1 year low of $29.45 and a 1 year high of $60.91.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.10. The firm had revenue of $151.75 million during the quarter, compared to analysts’ expectations of $147.13 million. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.51 earnings per share. Equities analysts forecast that Veracyte will post 1.32 earnings per share for the current fiscal year.

Insider Transactions at Veracyte

In related news, insider Phillip G. Febbo sold 13,110 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $43.05, for a total value of $564,385.50. Following the completion of the transaction, the insider owned 133,048 shares of the company’s stock, valued at approximately $5,727,716.40. This trade represents a 8.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Rebecca Chambers sold 3,652 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $43.10, for a total value of $157,401.20. Following the completion of the transaction, the chief financial officer owned 166,025 shares of the company’s stock, valued at $7,155,677.50. The trade was a 2.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 62,609 shares of company stock worth $2,858,904. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Veracyte

A number of institutional investors and hedge funds have recently modified their holdings of VCYT. Allspring Global Investments Holdings LLC boosted its stake in Veracyte by 7.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,795 shares of the biotechnology company’s stock valued at $742,000 after purchasing an additional 1,121 shares during the last quarter. Candriam S.C.A. increased its holdings in Veracyte by 38.1% during the 3rd quarter. Candriam S.C.A. now owns 186,387 shares of the biotechnology company’s stock worth $8,613,000 after purchasing an additional 51,392 shares in the last quarter. Alps Advisors Inc. purchased a new stake in shares of Veracyte in the third quarter worth approximately $648,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Veracyte in the third quarter worth approximately $388,000. Finally, Provenance Wealth Advisors LLC purchased a new stake in shares of Veracyte in the third quarter worth approximately $292,000.

Key Stories Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Veracyte reported Q3 adjusted earnings of $0.51 per share, above analyst estimates of $0.41, and revenue of $151.8 million, topping expectations of about $147.1 million. Revenue rose 15% year over year, including testing revenue of $146.4 million. Veracyte Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company authorized a $100 million share repurchase program, which may support shareholder returns and signal management confidence. Veracyte authorizes a Buyback Plan
• Positive Sentiment: Analysts’ average price target is reported at $55.78, indicating potential upside relative to the share price cited in the background information. Veracyte Stock Has Average Price Target of $55.78
• Neutral Sentiment: Despite the revenue increase, quarterly EPS matched the year-ago result of $0.51, so earnings growth has not yet reflected the stronger sales. Veracyte Tops Q3 Earnings and Revenue Estimates

Veracyte Company Profile

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.